Performance report Qtr3 201819 Jan 2019 Contents Executive summary Strategic highlights Approvals: timelines consistently being met for all but non-rec studies 74 of applicants rate our overall service highly slightly down on Qtr2
"Performance report Qtr3 2018/19 Jan 2019 Contents" is the property of its rightful owner. Permission is granted to
download and print the materials on this website for personal, non-commercial use only, and to display it
on your personal computer provided you do not modify the materials and that you retain all copyright
notices contained in the materials. By downloading content from our website, you accept the terms of this
agreement.
Share
Embed code
Presentation Transcript
01
Performance report Qtr3 2018/19
Jan 2019<br>
02
Contents<br>
03
Executive summary Strategic highlights
Approvals: timelines consistently being met for all but non-rec studies
74% of applicants rate our overall service highly slightly down on Qtr2
Transparency in Research survey published
Combined ways of working (CWOW) pilot well received. 24 applications. 18 complete.
Significant progress made in aligning processes with 4 Nations
Successful REC Chairs day held
New IRAS progressing at pace, phase 2 case submitted. Strategic challenges
Complexities arising from interoperability and multi stakeholder engagement are impacting on timelines for new IRAS development
Our ability to influence transparency agenda may be limited, HRA approach to be discussed at January Board
IT infrastructure replacement (future service programme) must be delivered by April 2020. HRA participates at Board level to mitigate this risk.
Budget pressure to year-end being actively managed - £50k - £100k.<br>
04
Strategic update KPIs, benefits and projects<br>
05
Championing health and social care research<br>
06
Championing health and social care research Transparency in Research survey published – 6th Dec
Transparency project communication management strategy drafted
Research integrity inquiry report vol 2 on Clinical Trials transparency published – HRA response well received by select committee and Ben Goldacre
Draft legal advice received on powers within existing legal framework, iro sanctions recommended by Select Committee
Meeting with Select Committee Chair, Norman Lamb<br>
07
Making it easier to conduct high quality research in the UK<br>
08
Making it easier to conduct high quality research in the UK<br>
09
Making it easier to conduct high quality research in the UK Technical Assurance - UK-wide QA procedure has been agreed and signed off
Sponsor- level IG standards - workshop to discuss held 16/11/18
SoECAT - Published via NIHR website
CWOW – pilot progressing well, 24 applications received, 18 complete
Four Nations - Local Information Template plan in place
Four Nations - Scotland and NI have agreed to use HARP to record outcomes<br>
10
Making it easier to conduct high quality research in the UK<br>
11
Making it easier to conduct high quality research in the UK<br>
12
Develop a pro-active, strategically focussed organisation<br>
13
Develop a pro-active, strategically focussed organisation Stakeholder engagement continues (Wellcome, MHRA, TranspariMed, Ben Goldacre)
Engagement material (slide, speaking notes, Q&A) developed and tested
REC Chairs day - 5th Dec
Consent to use of tissue and data - findings and next steps presented to UK Biobank annual showcase - 27th Nov
Brexit - response submitted to MHRA consultation on no-deal legislation for clinical trials of drugs and devices<br>
14
Capitalising on technological developments New IRAS development progressing with the current focus on interfaces, some delays experienced due to enhanced interoperability
Electronic Review of REC documents - new devices have been tested
HRA response to DHSC’s Policy Proposal: Developing the Framework for Safe Introduction and Use of Digital Health and Care Technology submitted on 2nd Nov
IT Infrastructure strategy and roadmap signed off
New Learning Management System live - end Nov<br>
15
Ensuring the HRA is governed effectively and provides value for the tax payer<br>
16
Ensuring the HRA is governed effectively and provides value for the tax payer<br>
